expecting something today., page-22

Thank you Blip Trader for your answer !

I agree with you in general that the GSK partnership is a done deal, but also support amg's description of the daunting unknown details about expected timelines towards such a deal, explaining our extremely reluctant market to appreciate our outlook.


Additional to your Aquafresh Ultimate quotes, the OBJ FIM technology would be ideal to reduce malodor in tackling the VSCs ( volatile sulfur compounds ) which are produced by dental debris and bacterias, especially under the dorsal tongue. The worst effected areas are dorsal posterior to the circumvallate papillae, which are unfortunately the areas which are particularly hard to reach and hence not enough effected by teeth brushing.

Aquafresh has a traditional advantage in lengthier reduction of VSC levels of up to 7 hours, compared to the usual 30 minutes effectiveness when used tongue scraping measures.

The delivery of active ingredients in the Aquafresh iso active foaming gel will be enhanced by using our technology reducing the amount of agents necessary in the product, hence reducing production costs, and also
enabling the compounds to reach the dorsal tongue more effectively.

Therefore I would support your guess of Aquafresh toothpaste being one of the targeted products for innovation using OBJ technologies.

Teeth whitening strips would be the candidate to use our ETP technologies, see OBJ's ann :

OBJ and GSK have agreed to work exclusively together with the
objective of developing new products which make use of OBJ's
proprietary Enhanced Transdermal Polymer (ETP) and Field In Motion
(FIM) technologies in the field of Oral Healthcare.

Since we have an exclusive collaboration for those applications, one wonders wether our ETP technologies are still available for other partners, raising the question wether the FMCG1 would indeed use the eM-Patch technology and the FMCG2 the newly added FIM technology patents.


It also would imply that GSK reserves the exclusive right for using the ETP technologies for their own pharmaceutical division as often argued on this forum, which would have wide ranging consequences as how far our collaboration with GSK really reaches.